Inebilizumab for Treatment of IgG4-Related Disease

In a trial involving 135 participants with IgG4-related disease, inebilizumab was associated with significantly lower flare risk and greater likelihood of complete remission than placebo at 1 year.

​   The New England Journal of Medicine: Search Results in Hematology/Oncology